RxDoctor Payments Data

Michael Fortson, MD

Family Medicine · Atlanta, GANPI 1972593705

Payments from drug & device makers

$759in general payments, 2019–2025

Across 26 payments — averaging $29.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$151
  • AbbVie$141
  • Johnson & Johnson$141
  • Gilead$92
  • Exact Sciences$58
  • Novo Nordisk$52
  • plus $124 from 3 others

What the payments were for

  • Food & beverage$759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company6$151
AbbVie(2 entities)2$141
Johnson & Johnson1$141
Gilead4$92
Exact Sciences3$58
Novo Nordisk3$52
Pfizer3$52
Amgen2$40
Lilly USA, LLC2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$759 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$76,638
Medicare patients
243
Services billed
655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$85,485
EliquisApixaban56$62,566
TrulicityDulaglutide39$43,003
JardianceEmpagliflozin32$38,359
JanuviaSitagliptin Phosphate17$19,389
FarxigaDapagliflozin Propanediol12$11,262
SymbicortBudesonide/Formoterol Fumarate31$10,162
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,981
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,876
Levothyroxine Sodium265$3,257
Albuterol Sulfate HfaAlbuterol Sulfate116$3,034
Azelastine Hcl133$2,548
Atorvastatin Calcium278$2,502
Doxepin Hcl14$2,425
Losartan Potassium223$2,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$52$85,48560 claims
PfizerEliquis$52$62,56656 claims
Lilly USA, LLCTrulicity$32$43,00339 claims
AbbVieSynthroid$141$1,46616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →